Rybelsus vs Ozempic: Oral Semaglutide vs Injectable Semaglutide
The Same Molecule, but Not the Same Treatment Experience Rybelsus and Ozempic both contain semaglutide, a GLP-1 receptor agonist used in type 2 diabetes. That shared active ingredient can make the choice look simpler than it is. One is taken by mouth every day and the other is injected under the skin once a week. […]
SOUL: Oral Semaglutide (Rybelsus) Demonstrates First-Ever Reduction in MACE for High-Risk Type 2 Diabetes Patients
Why the SOUL Trial Represents a Breakthrough for Oral GLP-1 Therapy The SOUL trial positions oral semaglutide in an entirely new therapeutic category. Until now, every GLP-1 receptor agonist with proven cardiovascular protection had been administered by injection. Liraglutide, injectable semaglutide, dulaglutide – each demonstrated reductions in major adverse cardiovascular events, establishing GLP-1 RAs as […]
Rybelsus for Weight Loss in 2026: How It Differs From the Wegovy Pill
Rybelsus is a once-daily oral semaglutide medicine used primarily for type 2 diabetes under its current U.S. labeling. Weight loss can occur during treatment, but Rybelsus is not approved specifically for chronic weight management. The regulatory landscape changed on December 22, 2025, when the FDA approved a separate oral semaglutide product—Wegovy tablets—for adults with obesity […]
Rybelsus Side Effects: Common, Long-Term, and Serious Risks
Most Rybelsus side effects involve the digestive system. Nausea is particularly characteristic, although abdominal pain, diarrhea, decreased appetite, vomiting, and constipation also occur. These symptoms are often most noticeable when treatment begins or the dose increases, and many people find that they ease as the body adjusts. Persistent vomiting, severe abdominal pain, inability to keep […]